natgillin/translations-raw huggingface dataset:
In a meta-analysis of 17 controlled clinical trials, elderly patients with dementia treated with other atypical antipsychotics, including risperidone, aripiprazole, olanzapine, and quetiapine had an increased risk of mortality compared to placebo. 
V metaanalizi 17 kontroliranih kliničnih preskušanj so pri starejših bolnikih z demenco, zdravljenih z drugimi atipičnimi antipsihotiki, na primer z risperidonom, aripiprazolom, olanzapinom in kvetiapinom ugotovili povečano tveganje smrtnosti v primerjavi s placebom.
This medicine must be taken by mouth, swallowed whole with water or other liquids. 
To zdravilo je treba jemati peroralno-tableto pogoltnite celo z vodo ali s kako drugo tekočino.
Paliperidone should not be used in patients with creatinine clearance below 10 mL/min. 
Paliperidon se ne sme uporabljati pri bolnikih z očistkom kreatinina, manjšim od 10 ml/min.
Other special populations No dose adjustment for INVEGA is recommended based on gender, race, or smoking status. 
Druge posebne skupine bolnikov Prilagajanje odmerka zdravila INVEGA glede na spol, raso ali kajenje ni potrebno.
• incontinence (lack of control) of urine, frequent passing of urine, inability to pass urine, pain when passing urine 
• uhajanje (nezmožnost nadzora) urina, pogosto uriniranje, nezmožnost uriniranja, bolečine ob uriniranju
Switching to other antipsychotic medicinal products There are no systematically collected data to specifically address switching patients from INVEGA to other antipsychotic medicinal products. 
Ni sistematično zbranih podatkov, ki bi posebej obravnavali prehod bolnika z zdravila INVEGA na druga antipsihotična zdravila.
In the up to 2-year, open-label treatment study of INVEGA in adolescents with schizophrenia, incidence of elevated serum prolactin levels occurred in 48% of females and 60% of males. 
V do 2-letni, odprti študiji zdravljenja z zdravilom INVEGA pri bolnikih s shizofrenijo so se pojavile povečane koncentracije prolaktina v plazmi pri 48% žensk in 60% moških.
The sedative effect of INVEGA should be closely monitored in this population. 
Pri tej populaciji je treba skrbno spremljati sedativni učinek zdravila INVEGA.
If signs and symptoms of tardive dyskinesia appear, the discontinuation of all antipsychotics, including INVEGA, should be considered. 
Če se pojavijo znaki in simptomi tardivne diskinezije, je treba razmisliti o prekinitvi uporabe vseh antipsihotikov, vključno z zdravilom INVEGA.
Repeat-dose toxicity studies of paliperidone in rat and dog showed mainly pharmacological effects, such as sedation and prolactin-mediated effects on mammary glands and genitals. 
Študije toksičnosti po dajanju večkratnih odmerkov paliperidona podganam in psom so pokazale predvsem farmakološke učinke, na primer sedacijo in prolaktinske učinke na mlečne žleze in na genitalije.
In vitro studies have shown that paliperidone is a P-glycoprotein (P-gp) substrate. 
In vitro študije so pokazale, da je paliperidon substrat P-glikoproteina (P-gp).
• increased GGT (a liver enzyme called gamma-glutamyltransferase) in your blood, increased liver enzymes in your blood 
• zvišana koncentracija GGT (jetrni encim, ki ga imenujemo gama glutamil transferaza) v krvi, zvišana koncentracija jetrnih encimov v krvi
Although no clear association with the administration of antipsychotics has so far been demonstrated in clinical and epidemiological studies, caution is recommended in patients with relevant medical history. 
Čeprav v kliničnih in epidemioloških študijah še niso ugotovili jasne povezave z uporabo antipsihotikov, pri bolnikih z ustrezno anamnezo priporočamo previdnost.
The dose may be increased or decreased by your doctor within the dose range of 3 mg to 12 mg once a day for schizophrenia or 6 mg to 12 mg once a day for schizoaffective disorder. 
Odmerek vam bo zdravnik lahko povečal ali zmanjšal v razponu od 3 mg do 12 mg enkrat na dan za shizofrenijo ali od 6 mg do 12 mg enkrat na dan za shizoafektivno motnjo.
Adolescents generally experienced side effects that were similar to those seen in adults except the following side effects were seen more commonly: 
Pri mladostnikih se na splošno pojavijo podobni neželeni učinki kot pri odraslih, razen naslednjih neželenih učinkov, ki se pri mladostnikih pojavijo pogosteje:
Patients with kidney problems Your doctor may adjust your dose of this medicine based upon your kidney function. 
Bolniki z okvaro ledvic Zdravnik bo morda prilagodil odmerek tega zdravila glede na delovanje vaših ledvic.
• neuroleptic malignant syndrome (confusion, reduced or loss of consciousness, high fever, and severe muscle stiffness) 
• nevroleptični maligni sindrom (zmedenost, zmanjšana stopnja zavesti ali nezavest, visoka telesna temperatura, in huda okorelost mišic)
Medicinal products affecting gastrointestinal transit time may affect the absorption of paliperidone, e.g., metoclopramide. 
Zdravila, ki vplivajo na čas prehoda skozi prebavila, lahko vplivajo na absorpcijo paliperidona npr.: metoklopramid.
The following are all the ADRs that were reported in clinical trials and post-marketing experience with paliperidone by frequency category estimated from INVEGA clinical trials in adults. 
V spodnji tabeli so navedeni vsi neželeni učinki o katerih so poročali v kliničnih preskušanjih in v obdobju trženja s paliperidonom po pogostnostih, ocenjenih v kliničnih preskušanjih zdravila INVEGA pri odraslih .
Paliperidone was not genotoxic in a battery of tests. 
Paliperidon ni bil genotoksičen v številnih različnih testih.
Efficacy of INVEGA over a flexible dose range of 3 mg/day to 9 mg/day in adolescent subjects (12 years and older) with schizophrenia (INVEGA N = 112, aripiprazole N = 114) was also evaluated in a randomised, double-blind, active-controlled study that included an 8-week, double-blind acute phase and an 18-week, double-blind maintenance phase. 
Učinkovitost zdravila INVEGA pri prilagodljivih odmerkih v razponu od 3 mg/dan do 9 mg/dan pri mladostnikih s shizofrenijo (starih 12 let in več) (zdravilo INVEGA N = 112, aripiprazol N = 114) so ocenili tudi v randomizirani, dvojno slepi, aktivno nadzorovani študiji, ki je vključevala 8-tedensko dvojno slepo akutno fazo in 18-tedensko, dvojno slepo vzdrževalno fazo.
In general, expected signs and symptoms are those resulting from an exaggeration of paliperidone's known pharmacological effects, i.e., drowsiness and sedation, tachycardia and hypotension, QT prolongation, and extrapyramidal symptoms. 
Na splošno lahko pričakujete znake in simptome, ki nastanejo kot posledica stopnjevanja znanih farmakoloških učinkov paliperidona, to je zaspanost in sedacijo, tahikardijo in hipotenzijo, podaljšanje intervala QT in ekstrapiramidne simptome.
• difficulty falling or staying asleep 
• motnje uspavanja ali spanca
Caution should be exercised when INVEGA is prescribed in patients with known cardiovascular disease or family history of QT prolongation, and in concomitant use with other medicines thought to prolong the QT interval. 
Pri predpisovanju zdravila INVEGA bolnikom z znano srčnožilno boleznijo ali s podaljšanjem intervala QT v družinski anamnezi ter pri njegovi sočasni uporabi z drugimi zdravili, ki tudi podaljšajo interval QT, je potrebna je previdnost.
INVEGA contains the active substance paliperidone which belongs to the class of antipsychotic medicines. 
Zdravilo INVEGA vsebuje učinkovino paliperidon, ki sodi v skupino antipsihotičnih zdravil.
Cardiovascular monitoring should commence immediately and should include continuous electrocardiographic monitoring for possible arrhythmias. 
Takoj začnite s spremljanjem srčnožilnega sistema, med drugim z neprekinjenim spremljanjem EKG, da ugotovite morebitne aritmije.
During treatment with INVEGA regular examination for extrapyramidal symptoms and other movement disorders should also be conducted. 
Med zdravljenjem z zdravilom INVEGA je potrebno redno preverjanje ekstrapiramidnih simptomov in ostalih gibalnih motenj.
Other medicines and INVEGA 
Druga zdravila in zdravilo INVEGA
In a 7-week juvenile toxicity study in rats administered oral doses of paliperidone up to 2.5 mg/kg/day, corresponding to an exposure approximately equal to the clinical exposure based on AUC, no effects on growth, sexual maturation and reproductive performance were observed. 
V 7-tedenski študiji toksičnosti pri novorojenih podganjih mladičih, ki so prejemali do največ 2,5 mg/kg/dan paliperidona peroralno, z izpostavljenostjo, približno enako klinični, na osnovi AUC, niso opažali učinkov na rast, spolno dozorevanje in sposobnost razmnoževanja.
The efficacy of INVEGA in the treatment of schizophrenia was established in three multi-centre, placebo-controlled, double-blind, 6-week trials in subjects who met DSM-IV criteria for schizophrenia. 
Učinkovitost zdravila INVEGA pri zdravljenju shizofrenije so ugotavljali v treh multicentričnih s placebom nadzorovanih dvojno slepih 6-tedenskih preskušanjih pri preiskovancih, ki so izpolnjevali kriterije DSM-IV za shizofrenijo.
- Patients with schizoaffective disorder treated with this medicine should be carefully monitored for a potential switch from manic to depressive symptoms. 
- Bolnike s shizoafektivno motnjo, ki jemljejo to zdravilo, je treba pozorno spremljati, ker lahko pri njih pride do prehoda iz maničnih v depresivne simptome.
Excipient with known effect Each 3 mg tablet contains 13.2 mg lactose. 
Pomožna snov z znanim učinkom Ena 3 mg tableta vsebuje 13,2 mg laktoze.
Each bottle contains two silica gel pouches which are provided to absorb moisture and keep the tablets dry. 
En vsebnik vsebuje dve blazinici s silicijevim oksidom, ki absorbira vlago in tako zagotavlja, da se tablete ne navlažijo.
• swollen tongue, stomach or intestinal infection, difficulty swallowing, excessive passing of gas or wind 
• otečen jezik, okužba želodca ali črevesja, oteženo požiranje, prekomerno izločanje plina in vetrov
Schizoaffective disorder (adults) 
Shizoafektivna motnja (odrasli)
• elated mood (mania), irritability, depression, anxiety 
• stanje vznesenosti (manija), razdražljivost, depresija, tesnoba
Neonates exposed to antipsychotics (including paliperidone) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. 
Pri novorojenčkih, ki so bili med tretjim trimesečjem nosečnosti izpostavljeni antipsihotikom (vključno s paliperidonom), obstaja tveganje za pojav neželenih učinkov, vključno z ekstrapiramidnimi in/ali odtegnitvenimi simptomi, katerih jakost in čas trajanja po porodu sta lahko različna.
In vitro studies have shown that paliperidone is a P-gp substrate and a weak inhibitor of P-gp at high concentrations. 
In vitro študije so pokazale, da je paliperidon substrat za P-glikoprotein (P-gp), in šibek zaviralec P-gp v visokih koncentracijah.
INVEGA has not been studied in elderly patients with dementia. 
Zdravila INVEGA niso proučevali pri starejših bolnikih z demenco.
INVEGA with alcohol Alcohol should be avoided when taking this medicine. 
Zdravilo INVEGA skupaj z alkoholom Med jemanjem tega zdravila se morate izogibati alkoholu.
In the case of acute overdosage, the possibility of multiple medicinal product involvement should be considered. 
V primeru akutnega prevelikega odmerjanja je treba upoštevati tudi možnost, da je bolnik hkrati zaužil več zdravil.
As diabetes mellitus or worsening of pre-existing diabetes mellitus have been seen with patients taking INVEGA, your doctor should check for signs of high blood sugar. 
Med jemanjem zdravila INVEGA so pri bolnikih opazili sladkorno bolezen ali njeno poslabšanje, zato bo vaš zdravnik preverjal znake zvišane koncentracije sladkorja v krvi.
Administration of paliperidone prolonged-release tablets with a standard high-fat/high-caloric meal increases Cmax and AUC of paliperidone by up to 50-60% compared with administration in the fasting state. 
Pri zaužitju paliperidona v tableti s podaljšanim sproščanjem z običajnim mastnim oz. visokokaloričnim obrokom se vrednosti Cmax in AUC za paliperidon povečajo za do 50-60% v primerjavi z zaužitjem zdravila na tešče.
Both studies included subjects who received INVEGA either as monotherapy or in combination with mood stabilisers and/or antidepressants. 
V obeh študijah so sodelovali preiskovanci, ki so zdravilo INVEGA prejemali kot samostojno zdravljenje ali pa v kombinaciji s stabilizatorji razpoloženja in/ali antidepresivi.
Following a single dose, INVEGA exhibits a gradual ascending release rate, allowing the plasma concentrations of paliperidone to steadily rise to reach peak plasma concentration (Cmax) approximately 24 hours after dosing. 
Po zaužitju enkratnega odmerka zdravila INVEGA postopno narašča njegova hitrost sproščanja, zaradi česar se plazemske koncentracije paliperidona ves čas zvišujejo in dosežejo največjo plazemsko koncentracijo (Cmax) približno 24 ur po jemanju zdravila.
INVEGA Flexible Dose (3-12 mg) 
INVEGA prilagodljivi odmerek (3-12 mg)
- Blisters: The tablets are supplied in blisters packed in cartons of 14, 28, 30, 49, 56, and 98 tablets. 
- Pretisni omoti: tablete so na voljo v škatlah s pretisnimi omoti po 14, 28, 30, 49, 56 in 98 tablet.
Based on in vitro studies utilising human liver enzymes, paliperidone is not a substrate for CYP1A2; smoking should, therefore, not have an effect on the pharmacokinetics of paliperidone. 
Na podlagi študij in vitro na človeških jetrnih encimih sklepamo, da paliperidon ni substrat izoencima CYP1A2, zato kajenje ne bi smelo vplivati na farmakokinetiko paliperidona.
Concomitant administration of INVEGA with paroxetine, a potent CYP2D6 inhibitor, showed no clinically significant effect on the pharmacokinetics of paliperidone. 
Pri sočasni uporabi zdravila INVEGA s paroksetinom, ki je močan zaviralec CYP2D6, ni bilo klinično pomembnih učinkov na farmakokinetiko paliperidona.
Taking the results of both studies together (pooled study-data), INVEGA improved the psychotic and manic symptoms of schizoaffective disorder at endpoint relative to placebo when administered either as monotherapy or in combination with mood stabilisers and/or antidepressants. 
Ko so združili rezultate obeh študij, je zdravilo INVEGA izboljšalo psihotične in manične simptome shizoafektivne motnje ob zaključku glede na placebo, če je bilo uporabljeno kot samostojno zdravljenje ali v kombinaciji s stabilizatorji razpoloženja in/ali antidepresivi.
• diabetes or worsening diabetes, high blood sugar, increased waist size, loss of appetite resulting in malnutrition and low body weight, high blood triglycerides (a fat) 
• sladkorna bolezen ali poslabšanje sladkorne bolezni, zvečana koncentracija sladkorja v krvi, povečan obseg pasu, izguba apetita, ki vodi v nezadostno prehrano in majhno telesno maso, visoke koncentracije trigliceridov (maščob) v krvi
Medicines with dopamine receptor antagonistic properties have been associated with the induction of tardive dyskinesia characterised by rhythmical, involuntary movements, predominantly of the tongue and/or face. 
Zdravila z antagonističnim delovanjem na dopaminske receptorje so lahko povezana z nastankom tardivne diskinezije, za katero so značilni ritmični nehoteni gibi, predvsem jezika in/ali obraza.
INVEGA should not be used during pregnancy unless clearly necessary. 
Zdravila INVEGA ne smete uporabljati med nosečnostjo, če ni nujno.
Patients treated with any atypical antipsychotic, including INVEGA, should be monitored for symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia, and weakness) and patients with diabetes mellitus should be monitored regularly for worsening of glucose control. 
Bolnike, zdravljene s katerim koli antipsihotikom, vključno z zdravilom INVEGA, moramo opazovati za simptome hiperglikemije (kot so polidipsija, poliurija in šibkost) ter redno spremljati bolnike s sladkorno boleznijo glede poslabšanja nadzora koncentracije glukoze v krvi.
The trial was stopped early for efficacy reasons by showing a significantly longer time to relapse in patients treated with INVEGA compared to placebo (p=0.0053). 
Preskušanje so ustavili predčasno zaradi učinkovitosti zdravila, saj je preskušanje pokazalo bistveno daljši čas do ponovnega izbruha bolezni pri bolnikih, zdravljenih z zdravilom INVEGA v primerjavi s placebom (p=0,0053).
In schizophrenia clinical trials, increases in serum prolactin were observed with INVEGA in 67% of subjects. 
V kliničnih preskušanjih shizofrenije so opazili povečanje koncentracije serumskega prolaktina pri jemanju zdravila INVEGA pri 67% preiskovancev.
Schizoaffective disorder: The safety and efficacy of INVEGA in the treatment of schizoaffective disorder in patients aged 12 to 17 years has not been studied or established. 
Shizoafektivna motnja: Varnost in učinkovitost zdravila INVEGA pri zdravljenje shizoafektivne motnje pri bolnikih, starih od 12 do 17 let nista bili preučevani ali dokazani.
There is no relevant use of INVEGA in children aged less than 12 years. 
Smotrne uporabe zdravila INVEGA pri otrocih, mlajših od 12 let, ni.
In a long-term trial designed to assess the maintenance of effect, the long-acting injectable formulation of paliperidone was significantly more effective than placebo in maintaining symptom control and delaying relapse of psychotic, manic, and depressive symptoms of schizoaffective disorder. 
V dolgotrajnem preskušanju za oceno ohranitve učinka so bile injekcije paliperidona s podaljšanim sproščanjem bistveno bolj učinkovite od placeba pri ohranjanju nadzora nad simptomi, zapoznitvi ponovnih izbruhov psihotičnih, maničnih in depresivnih simptomov pri shizoafektivni motnji.
INVEGA should be used with caution in patients with known cardiovascular disease (e.g., heart failure, myocardial infarction or ischaemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration and hypovolemia). 
Zdravilo INVEGA je treba uporabljati previdno pri bolnikih z znano srčnožilno boleznijo (npr. srčno popuščanje, miokardni infarkt ali ishemija, motnje prevajanja), z možganskožilnimi boleznimi ali s stanji, ki povečajo nagnjenost bolnika k hipotenziji (npr. dehidracija in hipovolemija).
Mon, Tue, Wed, Thu, Fri, Sat, Sun 
Pon, Tor, Sre, Čet, Pet, Sob, Ned
Population pharmacokinetics analysis revealed no evidence of race-related differences in the pharmacokinetics of paliperidone following INVEGA administration. 
Analiza populacijske farmakokinetike ni pokazala rasno pogojenih razlik v farmakokinetiki paliperidona po jemanju zdravila INVEGA.
In a study conducted in elderly subjects with schizophrenia, the safety profile was similar to that seen in non-elderly subjects. 
V študiji, opravljeni pri starejših preiskovancih s shizofrenijo, je bil profil varnosti zdravila podoben kot pri drugih preiskovancih.
What INVEGA is and what it is used for What you need to know before you take INVEGA How to take INVEGA 
Kaj je zdravilo INVEGA in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo INVEGA Kako jemati zdravilo INVEGA Možni neželeni učinki
• irregular heartbeat, abnormal electrical tracing of the heart (electrocardiogram or ECG), a fluttering or pounding feeling in your chest (palpitations) 
• nepravilno bitje srca, nepravilnosti v spremljanju električne aktivnosti srca(elektrokardiogram ali EKG), občutek trepetanja in razbijanja v prsih (palpitacije)
The efficacy of INVEGA in the acute treatment of psychotic or manic symptoms of schizoaffective disorder was established in two placebo-controlled, 6-week trials in non-elderly adult subjects. 
Učinkovitost zdravila INVEGA pri akutnem zdravljenju psihotičnih ali maničnih simptomov shizoafektivne motnje so ugotavljali v dveh s placebom nadzorovanih 6-tedenskih preskušanjih pri odraslih preiskovancih, ki niso bili starostniki.
Extrapyramidal symptoms (EPS) 
Ekstrapiramidni simptomi (EPS).
The apparent volume of distribution is 487 L. The plasma protein binding of paliperidone is 74%. 
Njegov navidezni porazdelitveni volumen je 487 l. Na plazemske beljakovine se veže v 74%, in sicer predvsem na α1-kisli glikoprotein in na albumin.
In vitro studies indicate that paliperidone is not an inducer of CYP1A2 activity. 
Študije in vitro kažejo, da paliperidon ne inducira aktivnosti encima CYP1A2.
The amount you take depends on how well the medicine works for you. 
Odvisen je od tega, kako dobro bo zdravilo pri vas delovalo.
In oral carcinogenicity studies of risperidone in rats and mice, increases in pituitary gland adenomas (mouse), endocrine pancreas adenomas (rat), and mammary gland adenomas (both species) were seen. 
Pri študijah peroralne kancerogenosti z risperidonom pri podganah in miših so opazili povečanje pogostnosti adenomov žleze hipofize (pri miših), adenomov endokrinega dela trebušne slinavke (pri podganah) in adenomov mlečne žleze (pri obeh vrstah).
INVEGA Medium Dose 3 or 6 mg* N=48 
INVEGA srednji odmerek 3 ali 6 mg* N=48
In a 40-week juvenile toxicity study in dogs with oral doses of risperidone (which is extensively converted to paliperidone) up to 5 mg/kg/day, effects on sexual maturation, long bone growth and femur mineral density were observed from 3 times the clinical exposure based on AUC. 
V 40-tedenski študiji toksičnosti pri mladih psih, ki so prejemali do največ 5 mg/kg/dan risperidona peroralno (ki se obsežno pretvori v paliperidon) so opazili učinke na spolno dozorevanje, rast dolgih kosti in mineralno gostoto stegnenice, ki so bili 3krat večji od klinične izpostavljenosti na osnovi AUC.
• lack of emotion 
• motnje čustvovanja
INVEGA should be used cautiously in patients with a history of seizures or other conditions that potentially lower the seizure threshold. 
Zdravilo INVEGA je treba uporabljati previdno pri bolnikih z epileptičnimi napadi v pretekli anamnezi ali z drugimi stanji, ki lahko znižajo prag za epileptični napad.
The experience from risperidone is considered valid also for paliperidone. 
Izkušnje z risperidonom veljajo tudi za paliperidon.
Conversely, on discontinuation of carbamazepine, the dose of INVEGA should be re-evaluated and decreased if necessary. 
Pri ukinjanju karbamazepina je prav tako potrebno ponovno oceniti odmerek zdravila INVEGA in ga po potrebi znižati.
INVEGA should be used with caution in elderly patients with dementia with risk factors for stroke (see section 4.4). 
Zdravilo INVEGA uporabljajte previdno pri starejših bolnikih z demenco in z dejavniki tveganja za možgansko kap (glejte poglavje 4.4).
Potential for gastrointestinal obstruction 
Možnost obstrukcije prebavil
As INVEGA has not been studied in patients with creatinine clearance below 10 mL/min, use is not recommended in such patients. 
Ker zdravila INVEGA niso proučevali pri bolnikih z očistkom kreatinina pod 10 ml/min, pri njih ne priporočamo njegove uporabe.
INVEGA Higher Dose (9-12 mg) 
INVEGA večji odmerek (9-12 mg)
Based on pooled data from the three, placebo-controlled, 6-week, fixed-dose trials with INVEGA (3, 6, 9, and 12 mg), orthostatic hypotension was reported by 2.5% of subjects treated with INVEGA compared with 0.8% of subjects treated with placebo. 
Po zbranih podatkih iz treh s placebom kontroliranih 6-tedenskih preskušanj s stalnimi odmerki zdravila INVEGA (3, 6, 9 in 12 mg) je ortostatsko hipotenzijo prijavilo 2,5% preiskovancev, zdravljenih z zdravilom INVEGA, v primerjavi z 0,8% preiskovancev, zdravljenih s placebom.
An approximately 3-fold increased risk of cerebrovascular adverse reactions have been seen in randomised placebo-controlled clinical trials in the dementia population with some atypical antipsychotics, including risperidone, aripiprazole, and olanzapine. 
V randomiziranih, s placebom kontroliranih kliničnih preskušanjih so pri skupini bolnikov z demenco ugotovili približno za 3-krat povečano tveganje za možganskožilne neželene učinke pri nekaterih atipičnih antipsihotikih, vključno z risperidonom, aripiprazolom in olanzapinom.
A minor decrease in the amount of active substance excreted unchanged in the urine suggests that there was little effect on the CYP metabolism or bioavailability of paliperidone during carbamazepine co-administration. 
Majhno znižanje količine učinkovine, ki se izloči nespremenjena z urinom kaže na to, da ima sočasno jemanje s karbamazepinom majhen učinek na metabolizem preko CYP ali biološko uporabnost paliperidona.